Market closedNon-fractional
Standard BioTools/LAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Standard BioTools
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Ticker
LAB
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
South San Francisco, United States
Employees
537
Website
www.standardbio.com
LAB Metrics
BasicAdvanced
$681M
Market cap
-
P/E ratio
-$1.02
EPS
1.66
Beta
-
Dividend rate
Price and volume
Market cap
$681M
Beta
1.66
Financial strength
Current ratio
4.505
Quick ratio
4.099
Long term debt to equity
5.44
Total debt to equity
15.918
Interest coverage (TTM)
-18.90%
Management effectiveness
Return on assets (TTM)
-9.39%
Return on equity (TTM)
-22.74%
Valuation
Price to revenue (TTM)
1.929
Price to book
1.21
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
-2.449
Growth
Revenue change (TTM)
31.27%
Earnings per share change (TTM)
-38.28%
3-year revenue growth
-4.01%
3-year earnings per share growth
10.22%
What the Analysts think about LAB
Analyst Ratings
Majority rating from 3 analysts.
LAB Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$46M
61.92%
Net income
-$32M
62.94%
Profit margin
-70.54%
0.63%
LAB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.22
-$0.27
-$0.25
-$0.27
-
Expected
-$0.21
-$0.12
-$0.13
-$0.13
-$0.10
Surprise
4.76%
125.00%
92.31%
116.00%
-
LAB News
AllArticlesVideos
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers
GlobeNewsWire·1 month ago
Lab Instrument Industry Update - New Commercial Entrants
Seeking Alpha·1 month ago
Standard BioTools to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Standard BioTools stock?
Standard BioTools (LAB) has a market cap of $681M as of July 05, 2024.
What is the P/E ratio for Standard BioTools stock?
The price to earnings (P/E) ratio for Standard BioTools (LAB) stock is 0 as of July 05, 2024.
Does Standard BioTools stock pay dividends?
No, Standard BioTools (LAB) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Standard BioTools dividend payment date?
Standard BioTools (LAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Standard BioTools?
Standard BioTools (LAB) has a beta rating of 1.66. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Standard BioTools stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.